Our team studies cerebrovascular disease physiopathology. Stroke is a devastating disease of sudden and commonly unpredictable onset. About 1.20 million strokes occur each year in the EU, and about 25% of men and 20% of women can expect to suffer a stroke if they live to be 85 years old. Aging is associated to gradual vascular dysfunction that can acquire diverse manifestations like small vessel disease, or multiple microinfarcts and microhemorrhages often associated with common pathologies such as arterial hypertension.

Tissue regeneration in acute renal damage and organ transplantation. Study of the mechanisms associated with regeneration, prevention and monitoring of ischemia/reperfusion damage, either associated with transplantation or in pathologies involving ischemic processes. Discovery and application of cellular and pharmacological therapies aimed at preventing tissue damage and promoting regeneration. In both cases the different members of the group are part of CIBEREHD (CIBER of hepatic and digestive diseases) and CIBER-BBN (CIBER of Bioengineering, Biomaterials and Nanomedicine) respectively.

The Neurobiology Unit investigates molecular mechanisms of neuronal death with the aim of identifying targets for therapeutic intervention in neurodegenerative diseases. Our team is also part of CIBERNED. The general lines of research are: 1) Molecular mechanisms of synapse elimination in models of Alzheimer's disease, 2) Regulation of mitochondrial DNA transcription and replication in genetic models of neurodegeneration. 3) Mitochondrial DNA as a biomarker in early stages of Parkinson's disease. This last line financed by the Michael J. Fox Foundation.

The group has a long trajectory in oxidative stress and lipid signaling in cell death. In particular, we have described the key role of mitochondrial GSH (GSHm) in mitochondrial function and susceptibility to apoptosis / necrosis. The dynamic properties of the membrane by the cholesterol / phospholipid ratio regulates the GSHm and its depletion sensitizes both hepatocytes and neurons to TNF / Fas, hypoxia and β-amyloid peptide, contributing to steatohepatitis and Niemann Pick and Alzheimer's diseases.

In our research group we are studying neuroinflammation in the context of neurodegenerative diseases and acute neuronal damage. It is suggested that neuroinflammation, in which activated glial cells (mainly microglia) are involved, play a role in the etiopathogenesis and/or in the progress of these pathologies. Our working hypothesis is that the modulation of neuroinflammation/glial activation can be a therapeutic strategy to act against the neuronal damage that occurs in neurodegenerative diseases and acute neuronal damage.

The goal of our group is to discover new therapeutic strategies to combat the underlying alterations of the cognitive loss in pathological brain aging. The research aims to enable or enhance endogenous neuroprotective mechanisms in experimental systems of aging and Alzheimer disease (AD). We mainly focus in the involvement of epigenetic changes against neuroinflammation-linked neurodegeneration. The group uses animal models, cell cultures and samples of human tissue to investigate neuroprotection and prevention therapies.

The Systems Neuropharmacology group examines the brain circuits and neuronal elements involved in the pathophysiology and treatment of major depression and schizophrenia, as well as in psychiatric and cognitive aspects of the Parkinson's disease. We use a wide range of experimental strategies in animal models, including molecular, histological, electrophysiological, neurochemical and behavioral approaches. This allows a detailed assessment of brain circuits at different levels of complexity, and facilitates the identification of new therapeutic targets.

Group in transformation due to retirement of the previous IP. Our research is focused on the study of the cellular and molecular aspects of neurodegenerative diseases with an inflammatory component. At present, the main research line is the study of GRP78-CB1R interaction and neuroprotection. Group members also participate in research projects led by PIs from other IIBB groups.

Study of pathological processes related to inflammation, fibrosis and tissue regeneration. Our research group focuses on the study of the regulatory mechanisms of inflammation and fibrosis using models of pancreatic and pulmonary pathologies. In particular, acute pancreatitis and idiopathic pulmonary fibrosis (IPF).

Our group focuses its research on the study of intracellular and intercellular mechanisms that are activated in response to injury, particularly in liver and neurodegenerative diseases as well as processes of carcinogenesis. Our work combines cell models and primary cultures with animal models that mimic human diseases. The ultimate goal is a better understanding of the signaling involved in diseases allows developing therapeutic interventions to improve the treatment of human disease. The main lines of research we address are: - Therapeutic targets in Alzheimer's disease (Dr.